Merck & CompanyvsOmada Health

MRK and OMDA stock compared: price, dividend, valuation and results, from SEC filings.

MRK

Merck & Company, Inc.

$144.46

Value $357B

-2.23%
MRK's page

Merck & Company (MRK) has a market value of $357B and Omada Health (OMDA) $899M. Over the last year, with dividends, MRK moved +60.0% and OMDA -27.7%. The P/E is 145.6 for MRK and 64.1 for OMDA. Dividend yield: MRK 2.35%, OMDA none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    MRK$357B

    OMDA$899M

    MRK is 397 times OMDA

  • Revenue, 12 months

    MRK$67.4B

    OMDA$333M

    MRK is 202 times OMDA

  • Net income, 12 months

    MRK$2.5B

    OMDA$14M

    MRK is 175 times OMDA

  • Operating margin

    MRK–

    OMDA2.1%

  • ROIC

    MRK3.9%

    OMDA2.3%

    1.6 points apart

  • P/E

    MRK145.6

    OMDA64.1

    MRK is 2.3 times OMDA

  • Dividend yield

    MRK2.4%

    OMDA0.0%

    2.4 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

MRK+60.1%

OMDA-27.7%

50100150DecFebAprJunAugOct
Returns by period
PeriodMRKWith dividendsOMDAWith dividends
1 year since November 14, 2025+60.0%Price +55.5%-27.7%Price -27.7%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

MRKMerck & CompanyOMDAOmada Health

Valuation

MRKOMDA
Valuation
Price$144.46$14.49
Market value$357B$899M
Enterprise value (EV)$401B$656M
P/E145.664.1
P/E, 5-year median14.8–
P/B8.03.3
EV/EBIT84.395.5
Free cash flow yield4.1%3.1%

Results and growth

MRKOMDA
Results and growth
Revenue, 12 months$67.4B$333M
Net income, 12 months$2.5B$14M
Free cash flow, 12 months$14.7B$28M
Earnings per share, 12 months$0.98$0.23
Revenue growth, year on year1.3%53.2%
Revenue growth a year, past+9.4%over 5 years+45.6%over 2 years
EPS growth a year, past+21.2%over 5 years–

Margins and returns on capital

MRKOMDA
Margins and returns on capital
Gross margin71.8%70.7%
Operating margin–2.1%
Net margin3.6%4.2%
ROIC3.9%2.3%
ROE5.2%5.8%

Balance sheet

MRKOMDA
Balance sheet
Cash$9.7B$243M
Total debt$53.8B$0
Net debt / EBITDA5.7-19.7
Interest cover2.4×22.4×

Dividends and buybacks

MRKOMDA
Dividends and buybacks
Dividend yield2.4%–
Dividend per share, 12 months$3.40–
Dividend growth a year, past+5.8%over 5 years–
Buyback yield1.4%–
Shareholder yield3.8%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: MRK or OMDA

Didn't find what you were looking for?

Ask us
Which is bigger, Merck & Company or Omada Health?

By market value, Merck & Company ($357B) is about 397.3 times Omada Health ($899M), at today's prices.

How did MRK and OMDA stock do over the last 1 years?

Since November 14, 2025, MRK's price moved +55.5% and OMDA's -27.7%. With dividends: MRK +60.0% (+60.0% a year), OMDA -27.7% (-27.7% a year). Past returns do not predict future ones.

Which pays the higher dividend, MRK or OMDA?

The dividend yield at today's price is 2.35% for Merck & Company and none for Omada Health. Over the last twelve months they paid $3.40 and – per share.

What is the P/E of MRK and OMDA?

At today's price, the P/E is 145.6 for MRK and 64.1 for OMDA. It is the share price over the last twelve months' earnings per share.

Which has the higher profit margins, Merck & Company or Omada Health?

Over the last twelve months, the net margin was 3.6% for Merck & Company and 4.2% for Omada Health, and the operating margin – and 2.1%. Revenue was $67.4B and $333M.

Which is the better investment, Merck & Company or Omada Health?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.